pembrolizumab,IMM60
merck,Portage
['melanoma', 'nsclc', 'sclc', 'portage']
we re pleased to share updated interim data on our lead #inkt engager in a phase 1/2 study for the treatment of #melanoma and #nsclc at #asco23. for more details on the poster, click here: 
Portage Biotech is developing first-in-class immuno-oncology therapies to help more patients achieve durable treatment responses and a better quality of life.